BioMarin Pharmaceutical Inc. (BMRN) is making a big bet on a little pill. On Tuesday, the company agreed to buy Alesta Therapeutics, a private biotech, for $275 million in cash upfront. The real prize here is ALE1, Alesta's lead experimental drug, which could become the first oral treatment for a rare genetic bone disorder called hypophosphatasia, or HPP.
This is a strategic move to fill a gap in BioMarin's portfolio. HPP is a nasty condition caused by mutations in the ALPL gene, leading to severe problems with bone and dental mineralization. Right now, the only approved therapy is Strensiq, an injectable enzyme replacement from AstraZeneca Plc (AZN), which pulled in about $1.7 billion in revenue last year. That's a big market, and BioMarin wants a piece of it with something that doesn't require a needle.
The Deal Details
Here's how the math works: BioMarin pays $275 million upfront to Alesta's shareholders. On top of that, there's the potential for an extra $215 million if ALE1 hits certain regulatory and development milestones. BioMarin says it will fund the whole thing from its existing cash reserves, so no need to go hat in hand to the capital markets.
But there's a twist. Before the deal closes later this quarter, Alesta will spin out all of its non-ALE1 assets and its current employees into a new, separate company. So BioMarin is essentially cherry-picking just the one drug it wants, leaving the rest behind. That's a clean way to avoid taking on stuff it doesn't need.
BioMarin also warned that the acquisition will have a "modestly dilutive" effect on its 2026 results, excluding the upfront payment. It plans to issue revised full-year guidance once the deal is done. So investors should expect some tweaks to the numbers in the coming months.
Why ALE1 Could Be a Game-Changer
ALE1 is an oral small molecule that's currently being tested in a Phase 1/2a trial. The study is looking at safety, tolerability, and pharmacodynamics in healthy volunteers and in adults with HPP. The idea is to lower excess inorganic pyrophosphate, which is what causes the mineralization problems in HPP.
Strensiq works differently: it's an injectable enzyme replacement that replaces the deficient tissue-nonspecific alkaline phosphatase. ALE1's approach is different, and if it works, the combination of being a pill and having a distinct mechanism could make it a strong contender in the treatment landscape. Patients would much rather swallow a pill than get an injection, so there's real potential here.
What the Analyst Says
William Blair has resumed coverage of BioMarin with a Market Perform rating. Analyst Sami Corwin thinks ALE1 is a logical addition to BioMarin's pipeline and believes the asset could create meaningful long-term value. Corwin points out that Strensiq's $1.7 billion in 2025 sales show there's a substantial market for HPP treatments, and ALE1 could carve out its own niche if it succeeds.
Of course, "if" is the operative word. ALE1 is still early-stage, and there's no guarantee it'll make it through the regulatory gauntlet. But BioMarin is clearly willing to pay up for the chance to disrupt a market that's currently dominated by a single injectable drug.
As for the stock, BioMarin shares were up 1.65% at $67.73 at the time of publication on Tuesday, according to market data. Investors seem to like the move, at least for now.
So, is this a smart bet or a costly gamble? Only time will tell. But for a company looking to strengthen its position in rare bone diseases, ALE1 could be just the ticket.
